Study on the clinical effect and mechanism of Wuwei Baogan Pill in treating nonalcoholic fatty liver disease
- Conditions
- non-alcoholic fatty liver disease
- Registration Number
- ITMCTR2000003950
- Lead Sponsor
- Qingdao Hospital of Traditional Chinese Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- Not specified
According to the guidelines for the diagnosis and treatment of non-alcoholic fatty liver disease (fatty liver and alcoholic liver disease Group of The Chinese Medical Association), the diagnostic criteria for non-alcoholic fatty liver disease and the TCM diagnosis are in line with the criteria for the syndrome of liver stagnation and spleen deficiency mainly combined with liver and kidney Yin deficiency and blood stasis blocking collateral.
1. Hepatitis virus marker positive;
2. Patients with other serious cardiovascular, liver, kidney, lung, brain and blood system diseases;
3. Allergic constitution or allergic to this drug;
4. Have used other drugs to treat alcoholic fatty liver disease within one month;
5. Pregnant or lactating women, psychopaths.
Study & Design
- Study Type
- Interventional study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method TCM syndrome score;color ultrasound;liver function;
- Secondary Outcome Measures
Name Time Method